Table 3

Independent predictors for progression-free and overall survival
Variables Progression-free survival Overall survival
Univariate Multivariate Univariate Multivariate
P value P value HR 95%CI P value P value HR 95%CI
Age, years 0.770 - - 0.578 - -
Male 0.028 0.443 - - 0.013 0.039 2.119 1.040-4.320
Etiology
Viral vs. others 0.252 - - 0.916 - -
Anti-viral therapy 0.325 - - 0.047 0.453 - -
HBV-DNA positivity 0.165 - - 0.231 - -
HBeAg positivity 0.234 - - 0.324 - -
Child-Pugh class, A vs. B 0.040 0.832 - - 0.787 - -
Liver cirrhosis 0.101 - - 0.002 0.005 2.319 1.281-4.201
GGT 0.001 0.012 1.003 1.001-1.004 0.014 0.068 - -
Tumor marker
Baseline AFP 0.008 0.049 1.000 1.000-1.001 0.486 - -
Baseline DCP 0.039 0.686 - - 0.001 0.028 1.000 1.000-1.001
AFP response 0.155 - - 0.023 <0.001 0.276 0.147-0.518
DCP response 0.756 - - 0.205 - -
BCLC stage, A vs. ≥B 0.002 0.409 - - 0.003 0.502 - -
Number of tumora 0.001 0.373 - - <0.001 0.030 1.443 1.035-2.011
Size of Tumorb 0.021 0.927 - - <0.001 0.085 - -
WHO response
CR + PR + SD vs. PD 0.419 - - 0.945 - -
mRECIST
CR + PR + SD vs. PD 0.107 - - 0.548 - -

anumber of measurable lesion, btotal size of measurable lesion.

HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; DCP, des gamma carboxy prothrombin; BCLC, Barcelona Clinic Liver Cancer.

Reference value: others, Child-Pugh class B, BCLC stage ≥ B, PD with WHO criteria, and PD with mRECIST criteria.

Lee et al.

Lee et al. BMC Cancer 2013 13:5   doi:10.1186/1471-2407-13-5

Open Data